Monitoring anti-PD-1-based immunotherapy in non-small cell lung cancer with FDG PET: introduction of iPERCIST
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Monitoring anti-PD-1-based immunotherapy in non-small cell lung cancer with FDG PET: introduction of iPERCIST
Authors
Keywords
PET, Fluorodeoxyglucose, Non-small cell lung cancer, Nivolumab, iPERCIST
Journal
EJNMMI Research
Volume 9, Issue 1, Pages -
Publisher
Springer Nature
Online
2019-01-29
DOI
10.1186/s13550-019-0473-1
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- The role of interim 18F-FDG PET/CT in prediction of response to ipilimumab treatment in metastatic melanoma
- (2018) Christos Sachpekidis et al. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
- Response criteria in solid tumors (PERCIST/RECIST) and SUVmax in early-stage non-small cell lung cancer patients treated with stereotactic body radiotherapy
- (2018) Cory Pierson et al. Radiation Oncology
- Absolute number of new lesions on 18F-FDG PET/CT is more predictive of clinical response than SUV changes in metastatic melanoma patients receiving ipilimumab
- (2017) Hoda Anwar et al. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
- Metabolic activity by 18F–FDG-PET/CT is predictive of early response after nivolumab in previously treated NSCLC
- (2017) Kyoichi Kaira et al. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
- Evaluating tumor response with FDG PET: updates on PERCIST, comparison with EORTC criteria and clues to future developments
- (2017) Katja Pinker et al. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
- Clinical characteristics of patient selection and imaging predictors of outcome in solid tumors treated with checkpoint-inhibitors
- (2017) Sabrina Rossi et al. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
- Prediction of Response to Immune Checkpoint Inhibitor Therapy Using Early-Time-Point 18 F-FDG PET/CT Imaging in Patients with Advanced Melanoma
- (2017) Steve Y. Cho et al. JOURNAL OF NUCLEAR MEDICINE
- 18F-FDG PET and CT Scans Detect New Imaging Patterns of Response and Progression in Patients with Hodgkin Lymphoma Treated by Anti–Programmed Death 1 Immune Checkpoint Inhibitor
- (2017) Laurent Dercle et al. JOURNAL OF NUCLEAR MEDICINE
- iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics
- (2017) Lesley Seymour et al. LANCET ONCOLOGY
- Symptomatic pseudo-progression followed by significant treatment response in two lung cancer patients treated with immunotherapy
- (2017) Maximilian J. Hochmair et al. LUNG CANCER
- Effectiveness and safety of nivolumab in advanced non-small cell lung cancer: The real-life data
- (2017) Elizabeth Dudnik et al. LUNG CANCER
- Comparison of RECIST, EORTC criteria and PERCIST for evaluation of early response to chemotherapy in patients with non-small-cell lung cancer
- (2016) Jingjie Shang et al. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
- Practical PERCIST: A Simplified Guide to PET Response Criteria in Solid Tumors 1.0
- (2016) Joo Hyun O et al. RADIOLOGY
- Classification and Pathology of Lung Cancer
- (2016) Min Zheng Surgical Oncology Clinics of North America
- Comparison of the RECIST and PERCIST criteria in solid tumors: a pooled analysis and review
- (2016) Seon Jeong Min et al. Oncotarget
- Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer
- (2015) Julie Brahmer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer
- (2015) Hossein Borghaei et al. NEW ENGLAND JOURNAL OF MEDICINE
- Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012
- (2014) Jacques Ferlay et al. INTERNATIONAL JOURNAL OF CANCER
- Non-Small Cell Lung Cancer: Epidemiology, Risk Factors, Treatment, and Survivorship
- (2012) Julian R. Molina et al. MAYO CLINIC PROCEEDINGS
- Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria
- (2009) J. D. Wolchok et al. CLINICAL CANCER RESEARCH
- From RECIST to PERCIST: Evolving Considerations for PET Response Criteria in Solid Tumors
- (2009) R. L. Wahl et al. JOURNAL OF NUCLEAR MEDICINE
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now